The posttraumatic stress disorder treatment market is expected to register a CAGR of more than 4 % over the forecast period, 2022-2027.
The COVID-19 pandemic is an unprecedented health concern that has significantly impacted the posttraumatic stress disorder (PTSD) treatment market. There are several studies conducted that indicate that COVID-19 increases the risk of PTSD, and this has led to an increase in demand for PTSD treatment. For instance, an August 2021 published article titled, "COVID‑19 and posttraumatic stress disorder: The perfect 'storm' for mental health (Review)" demonstrated that COVID-19 has a substantial impact on mental health and poses a significant risk for the development of trauma-related disorders, including PTSD among individuals who are most vulnerable, such as children, adolescents and COVID-19 survivors. Additionally, as per a February 2021 published article titled, "Posttraumatic Stress Disorder in Patients After Severe COVID-19 Infection", a cross-sectional study found a PTSD prevalence of 30.2% after acute COVID-19 infection, which is in line with findings in survivors of the previous coronavirus illnesses compared with findings reported after other types of collective traumatic events. Such studies indicate that the demand for PTSD treatment boosted amid the pandemic. Thus, the COVID-19 pandemic has positively impacted market growth.
The growth of the market can be attributed to the factors such as the increasing burden of post-traumatic stress disorder (PTSD) worldwide, the rise in the number of clinical trials pertaining to PTSD treatment as well as increasing research and development of novel therapies and drugs for PTSD.
The increasing burden of post-traumatic stress disorder is driving the demand for PTSD treatment that is majorly contributing to the market growth. For instance, a July 2021 published article titled, "Global burden of posttraumatic stress disorder and major depression in countries affected by the war between 1989 and 2019: a systematic review and meta-analysis" reported that out of twenty-two surveys for PTSD, 13 surveys for major depression (MD) and six surveys on the comorbidity of PTSD and MD were included. As per the study, random effects meta-analyses yielded a point prevalence of 26.51% for PTSD. The study also stated that the extrapolation yielded 316 million adult war survivors globally who suffered from PTSD and/or MD in 2019. Thus, the statistics from the study indicate the rising demand for PTSD treatment.
Additionally, as per an April 2022 update by SANE Australia, in Australia, around 1-2% of adults experience PTSD each year, while approximately 12% experience PTSD in their lifetime. This further indicates the significantly growing demand for PTSD treatment.
However, the rise in the number of clinical trials is also contributing to the market growth. For instance, in June 2020, SIU School of Medicine launched a clinical trial to study the safety and efficacy of an investigational drug for PTSD. Furthermore, in June 2021, ANANDA Scientific Inc., biotech pharmaceutical company, and NYU Grossman School of Medicine today reported the first patient was enrolled in a clinical trial evaluating Nantheia A1002N5S, an investigational drug using cannabidiol in ANANDA's proprietary Liquid Structure delivery technology as a treatment for Post-Traumatic Stress Disorder (PTSD) symptoms and Neurocognitive Impairment in patients with PTSD and with PTSD comorbid with Traumatic Brain Injury (TBI). Thus, due to the above-mentioned factors, the market is expected to grow significantly over the forecast period.
However, side effects associated with post-traumatic stress disorder treatment and the high cost of the treatment are the major factors hindering the market growth.
By drug class, antidepressants are expected to hold a significant share in the market. Antidepressants are medications used to treat post-traumatic stress disorder (PTSD). These medications aid in relieving symptoms of depression, anxiety, sleep problems, and concentration.
The selective serotonin reuptake inhibitor (SSRI) medications sertraline (Zoloft) and paroxetine (Paxil) are approved by the Food and Drug Administration (FDA) for PTSD treatment.
Alternative medications may sometimes be used off-label to treat PTSD. However, current guidelines do not recommend these medications to be used initially for PTSD treatment. These medications can include antidepressants like nefazodone (Serzone), imipramine (Tofranil), and phenelzine (Nardil). However, current guidelines do not recommend these medications to be used initially for PTSD treatment and include antidepressants such as nefazodone (Serzone), imipramine (Tofranil), and phenelzine (Nardil). Thus, the segment is expected to witness healthy growth over the forecast period.
The industry players are adopting competitive strategies, such as mergers & acquisitions, distribution channel enhancement, new product development, and research & development partnerships, to develop effective antidepressant drugs and hence, sustain themselves in the competition. For instance, in March 2022, Sun Pharma entered into an exclusive patent licensing agreement with Danish drugmaker Lundbeck to market and distribute its own version of antidepressant medication Vortioxetine in India under the brand name Vortidiftm. Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults.
Also, in August 2019, Lupin Limited (Lupin) announced the launch of its antidepressant drugs Fluoxetine Tablets USP, 10 mg and 20 mg, after receiving approval from the United States Food and Drug Administration (U.S. FDA) earlier. Lupin’s Fluoxetine Tablets USP, 10 mg and 20 mg, is the generic equivalent of Eli Lilly and Company’s Prozac Tablets, 10 mg and 20 mg. Thus, such product launches are predicted to offer a potential growth platform for antidepressants.
Within North America, the United States has held the major share of the market. The major factors propelling the market growth in the country are the increasing burden of post-traumatic stress disorder, growth in research and development activities as well as presence of strong and established market players.
The high burden of PTSD is driving the demand for PTSD treatment in the country. For instance, as per an August 2020 update by the American Psychiatric Association, PTSD affects approximately 3.5 percent of United States adults every year, and an estimated one in 11 people will be diagnosed with PTSD in their lifetime, and women are twice as likely as men to have PTSD.
Moreover, in June 2021, Tarzana Treatment Centre celebrated National PTSD Awareness Day in the United States, a point in time when more Americans than ever before are suffering from post-traumatic stress disorder. Thus, such developments indicate the rising awareness regarding PTSD that is increasing the demand for its treatment.
Also, the rising number of clinical trials for new drug development for the treatment of post-traumatic stress disorder treatment is expected to drive the regional market growth over the forecast period. For instance, Otsuka Pharmaceutical Development & Commercialization, Inc. initiated a clinical trial for Brexpiprazole as a combination therapy with Sertraline in the treatment of adults with PTSD. The trial is in phase 3. The study was initiated in October 2019 and is expected to conclude in June 2022. Brexpiprazole is an atypical antipsychotic used in the treatment of schizophrenia and other major depressive disorders. Thus, due to the above-mentioned factors, the market is expected to witness significant growth over the forecast period.
The Post Traumatic Stress Disorder Treatment Market is competitive with the presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are Lupin Limited, Pfizer Inc., Aurobindo Pharma Limited, GlaxoSmithKline plc. and Merck KGaA.
This product will be delivered within 2 business days.
The COVID-19 pandemic is an unprecedented health concern that has significantly impacted the posttraumatic stress disorder (PTSD) treatment market. There are several studies conducted that indicate that COVID-19 increases the risk of PTSD, and this has led to an increase in demand for PTSD treatment. For instance, an August 2021 published article titled, "COVID‑19 and posttraumatic stress disorder: The perfect 'storm' for mental health (Review)" demonstrated that COVID-19 has a substantial impact on mental health and poses a significant risk for the development of trauma-related disorders, including PTSD among individuals who are most vulnerable, such as children, adolescents and COVID-19 survivors. Additionally, as per a February 2021 published article titled, "Posttraumatic Stress Disorder in Patients After Severe COVID-19 Infection", a cross-sectional study found a PTSD prevalence of 30.2% after acute COVID-19 infection, which is in line with findings in survivors of the previous coronavirus illnesses compared with findings reported after other types of collective traumatic events. Such studies indicate that the demand for PTSD treatment boosted amid the pandemic. Thus, the COVID-19 pandemic has positively impacted market growth.
The growth of the market can be attributed to the factors such as the increasing burden of post-traumatic stress disorder (PTSD) worldwide, the rise in the number of clinical trials pertaining to PTSD treatment as well as increasing research and development of novel therapies and drugs for PTSD.
The increasing burden of post-traumatic stress disorder is driving the demand for PTSD treatment that is majorly contributing to the market growth. For instance, a July 2021 published article titled, "Global burden of posttraumatic stress disorder and major depression in countries affected by the war between 1989 and 2019: a systematic review and meta-analysis" reported that out of twenty-two surveys for PTSD, 13 surveys for major depression (MD) and six surveys on the comorbidity of PTSD and MD were included. As per the study, random effects meta-analyses yielded a point prevalence of 26.51% for PTSD. The study also stated that the extrapolation yielded 316 million adult war survivors globally who suffered from PTSD and/or MD in 2019. Thus, the statistics from the study indicate the rising demand for PTSD treatment.
Additionally, as per an April 2022 update by SANE Australia, in Australia, around 1-2% of adults experience PTSD each year, while approximately 12% experience PTSD in their lifetime. This further indicates the significantly growing demand for PTSD treatment.
However, the rise in the number of clinical trials is also contributing to the market growth. For instance, in June 2020, SIU School of Medicine launched a clinical trial to study the safety and efficacy of an investigational drug for PTSD. Furthermore, in June 2021, ANANDA Scientific Inc., biotech pharmaceutical company, and NYU Grossman School of Medicine today reported the first patient was enrolled in a clinical trial evaluating Nantheia A1002N5S, an investigational drug using cannabidiol in ANANDA's proprietary Liquid Structure delivery technology as a treatment for Post-Traumatic Stress Disorder (PTSD) symptoms and Neurocognitive Impairment in patients with PTSD and with PTSD comorbid with Traumatic Brain Injury (TBI). Thus, due to the above-mentioned factors, the market is expected to grow significantly over the forecast period.
However, side effects associated with post-traumatic stress disorder treatment and the high cost of the treatment are the major factors hindering the market growth.
Key Market Trends
Antidepressants Segment is Expected to Hold a Significant Market Share in the Post Traumatic Stress Disorder Treatment Market
By drug class, antidepressants are expected to hold a significant share in the market. Antidepressants are medications used to treat post-traumatic stress disorder (PTSD). These medications aid in relieving symptoms of depression, anxiety, sleep problems, and concentration.
The selective serotonin reuptake inhibitor (SSRI) medications sertraline (Zoloft) and paroxetine (Paxil) are approved by the Food and Drug Administration (FDA) for PTSD treatment.
Alternative medications may sometimes be used off-label to treat PTSD. However, current guidelines do not recommend these medications to be used initially for PTSD treatment. These medications can include antidepressants like nefazodone (Serzone), imipramine (Tofranil), and phenelzine (Nardil). However, current guidelines do not recommend these medications to be used initially for PTSD treatment and include antidepressants such as nefazodone (Serzone), imipramine (Tofranil), and phenelzine (Nardil). Thus, the segment is expected to witness healthy growth over the forecast period.
The industry players are adopting competitive strategies, such as mergers & acquisitions, distribution channel enhancement, new product development, and research & development partnerships, to develop effective antidepressant drugs and hence, sustain themselves in the competition. For instance, in March 2022, Sun Pharma entered into an exclusive patent licensing agreement with Danish drugmaker Lundbeck to market and distribute its own version of antidepressant medication Vortioxetine in India under the brand name Vortidiftm. Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults.
Also, in August 2019, Lupin Limited (Lupin) announced the launch of its antidepressant drugs Fluoxetine Tablets USP, 10 mg and 20 mg, after receiving approval from the United States Food and Drug Administration (U.S. FDA) earlier. Lupin’s Fluoxetine Tablets USP, 10 mg and 20 mg, is the generic equivalent of Eli Lilly and Company’s Prozac Tablets, 10 mg and 20 mg. Thus, such product launches are predicted to offer a potential growth platform for antidepressants.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
Within North America, the United States has held the major share of the market. The major factors propelling the market growth in the country are the increasing burden of post-traumatic stress disorder, growth in research and development activities as well as presence of strong and established market players.
The high burden of PTSD is driving the demand for PTSD treatment in the country. For instance, as per an August 2020 update by the American Psychiatric Association, PTSD affects approximately 3.5 percent of United States adults every year, and an estimated one in 11 people will be diagnosed with PTSD in their lifetime, and women are twice as likely as men to have PTSD.
Moreover, in June 2021, Tarzana Treatment Centre celebrated National PTSD Awareness Day in the United States, a point in time when more Americans than ever before are suffering from post-traumatic stress disorder. Thus, such developments indicate the rising awareness regarding PTSD that is increasing the demand for its treatment.
Also, the rising number of clinical trials for new drug development for the treatment of post-traumatic stress disorder treatment is expected to drive the regional market growth over the forecast period. For instance, Otsuka Pharmaceutical Development & Commercialization, Inc. initiated a clinical trial for Brexpiprazole as a combination therapy with Sertraline in the treatment of adults with PTSD. The trial is in phase 3. The study was initiated in October 2019 and is expected to conclude in June 2022. Brexpiprazole is an atypical antipsychotic used in the treatment of schizophrenia and other major depressive disorders. Thus, due to the above-mentioned factors, the market is expected to witness significant growth over the forecast period.
Competitive Landscape
The Post Traumatic Stress Disorder Treatment Market is competitive with the presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are Lupin Limited, Pfizer Inc., Aurobindo Pharma Limited, GlaxoSmithKline plc. and Merck KGaA.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Jazz Pharmaceuticals
- Mydecine Innovations Group
- Tonix Pharmaceuticals
- Otsuka Pharmaceutical Co., Ltd.
- Lupin Limited
- Teva Pharmaceutical Industries Ltd.
- Merck KGaA
- Pfizer Inc.
- Aurobindo Pharma Limited
- GlaxoSmithKline plc
- Viatris Inc.
- Jubilant Pharmova
Methodology
LOADING...
